Under the Office of the Chief Scientist in the Office of the Commissioner, FDA has chartered an Alternative Methods Working Group with representatives from all of FDA. The goals of this work group are to strengthen FDA’s long commitment to promoting the development and use of new technologies and to reduce animal testing, to discuss new alternative in vitro/in silico/in vivo methods across FDA and to interact with federal government partners and other global stakeholders to facilitate discussion and development of draft performance criteria for such assays.